

Performance Information by Measure

Report Includes Data from the July through November 2007 TAP Files Only

Measure Statement	QDC Exclusion Instances					Clinical Performance Not Met				Clinical Performance Met (Numerator)	Clinical Performance Denominator	National Clinical Performance Rate ^c		
	Clinical (1P)	Patient (2P)	System (3P)	Other ^a	Total Instances Excluded	QDC Reported ^b	QDC Not Reported	Insufficient QDC Information	Total Performance Not Met			25th Percentile	50th Percentile	75th Percentile
Advance Care														
#47 Advance Care Plan		34,586			34,586	145,785	325,598	102	471,485	154,242	625,727	2.29%	15.79%	39.60%
Asthma														
#53 Pharmacologic Therapy				14	14	0	15	16	31	84	115	50.00%	100.00%	100.00%
#64 Asthma Assessment						2	15	0	17	66	83	100.00%	100.00%	100.00%
Breast Cancer														
#71 Hormonal Therapy for Stage IC-III, ER/PR Positive Breast Ca				11,663	11,663	1,571	46,735	2	48,308	34,089	82,397	15.38%	40.00%	66.67%
CABG														
#43 Use of IMA in CABG Surgery	420				420	192	3,997	3	4,192	8,977	13,169	51.72%	78.57%	100.00%
#44 Pre-Operative Beta-Blocker in Isolated CABG Surgery	441				441	580	3,079	2	3,661	5,326	8,987	37.04%	66.67%	90.32%
Cataracts														
#15 Assessment of Visual Functional Status	7,911				7,911	11,637	174,832	304	186,773	391,035	577,808	36.36%	72.13%	91.69%
#16 Doc of Pre-Surgical Axial Length, Corneal Power Measurement and Method of Intraocular Lens Power Calculation	411			987	1,398	0	53,122	4	53,126	164,145	217,271	62.22%	87.76%	97.67%
#17 Pre-Surgical Dilated Fundus Evaluation		134			134	1,484	50,809	40	52,333	153,869	206,202	59.82%	86.27%	96.63%
Chemotherapy														
#73 Plan Documented Before Chemotherapy Administered						113	10,986	0	11,099	15,792	26,891	33.93%	65.38%	87.50%
Chest Pain														
#54 ECG Performed for Non-Traumatic Chest Pain	768	138			906	10,960	47,615	3	58,578	206,784	265,362	66.67%	87.50%	100.00%
Colon Cancer														
#72 Chemotherapy for Stage III				2,984	2,984	421	9,633	1	10,055	5,003	15,058	13.33%	31.58%	58.33%
Chronic Obstructive Pulmonary Disease (COPD)														
#51 Spirometry	1,266	361	211		1,838	3,025	19,727	0	22,752	29,285	52,037	25.00%	57.14%	87.50%
#52 Bronchodilator Therapy	367	91	6	5,821	6,285	152	16,247	3,547	19,946	20,071	40,017	1.87%	42.86%	77.27%
Coronary Artery Disease														
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	20,071	1,882	871		22,824	7,320	136,943	0	144,263	382,711	526,974	50.00%	79.07%	95.00%
#7 Beta-Blocker Therapy for CAD Patients with Prior MI	2,292	347	78		2,717	394	5,615	0	6,009	24,922	30,931	50.00%	87.50%	100.00%
Depression														
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of Major Depression				1,977	1,977	199	1,611	1	1,811	1,243	3,054	14.93%	61.25%	100.00%
Diabetes														
#1 Hemoglobin A1c - Poor Control ^d				8,365	8,365	17,002	86,878	780	158,965	104,660	263,625	14.29%	33.33%	60.00%
#2 LDL Control						65,389	82,079	862	148,330	109,362	257,692	22.22%	42.86%	60.00%
#3 High Blood Pressure Control						70,473	82,407	7,107	159,987	102,893	262,880	18.01%	38.89%	56.76%
ESRD														
#37 Dialysis Dose				2,023	2,023	9,752	28,214	9	37,975	41,320	79,295	29.90%	52.17%	68.62%

Measure Statement	QDC Exclusion Instances					Clinical Performance Not Met				Clinical Performance Met (Numerator)	Clinical Performance Denominator	National Clinical Performance Rate ^c		
	Clinical (1P)	Patient (2P)	System (3P)	Other ^a	Total Instances Excluded	QDC Reported ^b	QDC Not Reported	Insufficient QDC Information	Total Performance Not Met			25th Percentile	50th Percentile	75th Percentile
#38 Hematocrit Level				903	903	15,290	26,739	3	42,032	38,791	80,823	28.57%	47.89%	63.33%
Fall Risk														
#4 Screening for Future Fall Risk	2,787				2,787	13,840	271,729	1,866	287,435	205,723	493,158	18.62%	50.00%	75.06%
GERD														
#60 Assessment for Alarm Symptoms	106			8,930	9,036	673	7,271	3	7,947	8,317	16,264	28.21%	62.17%	94.29%
#61 Upper Endoscopy for Patients with Alarm Symptoms	74	21	2	10,620	10,717	32	7,191	5,844	13,067	1,615	14,682	0.00%	0.00%	22.22%
#62 Biopsy for Barrett's Esophagus	35			3,598	3,633	20	2,809	383	3,212	1,310	4,522	0.00%	16.67%	61.54%
#63 Barium Swallow - Inappropriate Use	65			6,009	6,074	68	5,604	12	5,684	3,740	9,424	20.00%	50.00%	83.33%
Primary Open Angle Glaucoma														
#12 Optic Nerve Evaluation	8,396				8,396	10,175	151,775	168	162,118	341,048	503,166	38.46%	71.55%	91.14%
Heart Failure														
#5 ACE Inhibitor or ARB Therapy for LVSD	3,592	306	106	32,863	36,867	541	24,130	8,291	32,962	32,002	64,964	4.76%	50.00%	82.61%
#8 Beta-Blocker Therapy for LVSD	1,563	231	33	31,083	32,910	263	21,682	8,070	30,015	32,895	62,910	5.56%	50.00%	88.89%
Imaging Stroke														
#10 CT or MRI Reports				12,830	12,830	6,210	21,225	2,129	29,564	17,248	46,812	0.00%	33.33%	62.50%
#11 Carotid Imaging Reports	687				687	3,155	5,950	0	9,105	7,807	16,912	0.00%	50.00%	100.00%
Chronic Lymphocytic Leukemia (CLL)														
#70 Baseline Flow Cytometry	144	22	109		275	248	3,022	0	3,270	5,194	8,464	38.89%	66.67%	92.86%
Macular Degeneration														
#13 Age-Related Eye Disease Study (AREDS) Prescribed/Recommended	13,058				13,058	6,391	97,161	232	103,784	172,850	276,634	33.33%	64.50%	87.50%
#14 Dilated Macular Examination	2,706	649			3,355	2,721	90,537	15	93,273	210,463	303,736	38.64%	70.00%	91.33%
Myelodysplastic Syndrome (MDS) and Acute Leukemias														
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	127	97	106		330	646	3,830	0	4,476	5,504	9,980	25.00%	50.00%	83.33%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy			78	1,241	1,319	30	3,355	617	4,002	3,572	7,574	2.50%	33.33%	66.67%
Medication Reconciliation														
#46 Medication Reconciliation						336	13,620	1,767	15,723	4,578	20,301	2.56%	22.73%	50.00%
Melanoma														
#25 Patient Medical History	169	12	35		216	212	5,015	0	5,227	16,821	22,048	60.00%	89.19%	100.00%
#26 Complete Physical Skin Examination	204	346	73		623	224	5,143	0	5,367	16,136	21,503	57.14%	86.67%	100.00%
#27 Counseling on Self-Examination	120	22	93		235	250	5,393	0	5,643	15,928	21,571	57.14%	84.62%	100.00%
Multiple Myeloma														
#69 Treatment with Bisphosphonates	877	105			982	250	2,907	1	3,158	3,857	7,015	33.33%	62.83%	100.00%
Myocardial Infarction														
#28 Aspirin at Arrival	281	71			352	1,429	1,419	1	2,849	6,731	9,580	50.00%	100.00%	100.00%
#29 Beta-Blocker at Time of Arrival				282	282	550	401	2	953	1,238	2,191	0.00%	66.67%	100.00%
Osteoporosis														
#24 Osteoporosis: Communication with the Physician Managing Ongoing Care Post Fracture	72	11			83	446	2,869	0	3,315	1,358	4,673	7.69%	22.58%	52.17%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	3,799	4,484	1,496		9,779	20,881	219,979	0	240,860	123,160	364,020	8.70%	26.69%	55.32%

Measure Statement	QDC Exclusion Instances					Clinical Performance Not Met				Clinical Performance Met (Numerator)	Clinical Performance Denominator	National Clinical Performance Rate ^c		
	Clinical (1P)	Patient (2P)	System (3P)	Other ^a	Total Instances Excluded	QDC Reported ^b	QDC Not Reported	Insufficient QDC Information	Total Performance Not Met			25th Percentile	50th Percentile	75th Percentile
#40 Osteoporosis: Management Following Fracture	59	56	59		174	364	2,080	0	2,444	875	3,319	8.33%	40.00%	100.00%
#41 Osteoporosis: Pharmacologic Therapy	1,235	1,005	126		2,366	974	12,782	0	13,756	25,470	39,226	42.86%	71.43%	100.00%
#42 Counseling for Vitamin D, Calcium Intake, and Exercise	265				265	934	8,393	31	9,358	21,684	31,042	40.00%	73.33%	100.00%
Perioperative Care														
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	916				916	1,377	42,597	39	44,013	63,987	108,000	33.33%	66.67%	90.43%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	2,159				2,159	1,529	34,313	7	35,849	43,661	79,510	30.00%	58.33%	85.71%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	785			911	1,696	672	25,353	12,916	38,941	21,542	60,483	0.00%	25.00%	68.42%
#23 VTE Prophylaxis	517				517	1,618	19,544	0	21,162	28,591	49,753	33.33%	61.54%	88.89%
#30 Timing of Prophylactic Antibiotic - Administering Physician						25,216	11,279	57	36,552	318,820	355,372	90.00%	100.00%	100.00%
#45 Discontinuation of Prophylactic Antibiotics	291			202	493	78	13,690	6,097	19,865	17,635	37,500	1.54%	50.00%	87.50%
Pharyngitis														
#66 Appropriate Testing for Children						0	0	0	0	0	0	0.00%	0.00%	0.00%
Pneumonia														
#56 Vital Signs for Community-Acquired Bacterial Pneumonia						2,710	9,256	3	11,969	53,290	65,259	72.73%	100.00%	100.00%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	193	28	48		269	8,909	10,153	0	19,062	61,894	80,956	61.54%	100.00%	100.00%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia						2,455	8,561	14	11,030	45,593	56,623	71.43%	100.00%	100.00%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	239	33	52		324	3,712	8,289	0	12,001	36,727	48,728	66.67%	100.00%	100.00%
Radiation Therapy (RT)														
#74 RT Recommended for Invasive Breast Ca Patients with Breast Conserving Surgery				120	120	59	427	0	486	678	1,164	42.86%	66.67%	100.00%
Retinopathy														
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	418	80			498	591	26,228	3	26,822	67,677	94,499	50.00%	83.33%	100.00%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	510	83		645	1,238	1,310	25,344	31,863	58,517	38,912	97,429	0.00%	33.33%	80.00%
Stroke and Stroke Rehabilitation														
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	154	23			177	185	1,174	0	1,359	1,817	3,176	33.33%	66.67%	100.00%
#32 Discharged on Antiplatelet Therapy	235	30			265	194	2,075	0	2,269	2,364	4,633	33.33%	54.70%	100.00%
#33 Anticoagulant Therapy Prescribed for Afib at Discharge	7				7	2	0	0	2	25	27	100.00%	100.00%	100.00%
#34 t-PA Considered				974	974	153	849	261	1,263	271	1,534	0.00%	0.00%	50.00%
#35 Screening for Dysphagia	41			183	224	61	967	830	1,858	617	2,475	0.00%	14.29%	62.50%
#36 Consideration of Rehabilitation Services						241	1,153	14	1,408	1,713	3,121	33.33%	66.67%	100.00%
Syncope														
#55 ECG Performed for Syncope	161	58			219	3,482	10,782	1	14,265	61,055	75,320	70.00%	100.00%	100.00%
Upper Respiratory Infection														

Measure Statement	QDC Exclusion Instances				Clinical Performance Not Met				Clinical Performance Met (Numerator)	Clinical Performance Denominator	National Clinical Performance Rate ^c			
	Clinical (1P)	Patient (2P)	System (3P)	Other ^a	Total Instances Excluded	QDC Reported ^b	QDC Not Reported	Insufficient QDC Information			Total Performance Not Met	25th Percentile	50th Percentile	75th Percentile
#65 Appropriate Treatment for Children						0	0	0	0	1	1	100.00%	100.00%	100.00%

Measure Statement	QDC Exclusion Instances					Clinical Performance Not Met				Clinical Performance Met (Numerator)	Clinical Performance Denominator	National Clinical Performance Rate ^c		
	Clinical (1P)	Patient (2P)	System (3P)	Other ^a	Total Instances Excluded	QDC Reported ^b	QDC Not Reported	Insufficient QDC Information	Total Performance Not Met			25th Percentile	50th Percentile	75th Percentile
Urinary Incontinence														
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	1,815				1,815	8,758	61,143	58	69,959	43,578	113,537	11.70%	35.45%	65.10%
#49 Characterization of UI in Women Aged 65 Years and Older						210	4,907	15	5,132	11,372	16,504	48.15%	75.00%	96.00%
#50 Plan of Care for UI in Women Aged 65 Years and Older						395	4,970	43	5,408	10,907	16,315	40.00%	71.43%	93.40%

^a Includes instances where an 8P modifier, G-code, or CPT II code is used as a performance exclusion for the measure.

^b Includes instances where an 8P modifier, G-code, or CPT II code is used to indicate the quality action was not provided for a reason not otherwise specified.

^c The National Comparison for Performance includes performance information for all NPI/TIN combinations submitting at least one quality-data code for the measure. The 25th percentile indicates that 25% of the NPI/TIN combinations participating nationally are performing at or below this rate, the 50th percentile indicates that 50% of the NPI/TIN combinations participating nationally are performing at or below this rate, and the 75th percentile indicates that 75% of the NPI/TIN combinations participating nationally are performing at or below this rate.

^d A lower performance rate indicates better performance for poor control measures.

Note: The shaded cells indicate that specific exclusion code is not applicable for the measure.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recently received pilot participant list from ORD).